An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment With OncoVEX^GM-CSF for Eligible Melanoma Patients Participating in Study 005/05

Trial Profile

An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment With OncoVEX^GM-CSF for Eligible Melanoma Patients Participating in Study 005/05

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Dec 2015

At a glance

  • Drugs Talimogene laherparepvec (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Acronyms OPTIM-extension
  • Sponsors BioVex
  • Most Recent Events

    • 08 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 15 Feb 2015 Status changed from recruiting to active, no longer recruiting, according to M.D. Anderson Cancer Center.
    • 06 Mar 2013 Actual initiation date changed from Oct 2010 to 8 Feb 2012 as reported by Vanderbilt-Ingram Cancer Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top